TY - JOUR
T1 - Impacts of drug interactions on pharmacokinetics and the brain transporters
T2 - A recent review of natural compound-drug interactions in brain disorders
AU - Khadka, Bikram
AU - Lee, Jae Young
AU - Park, Eui Kyun
AU - Kim, Ki Taek
AU - Bae, Jong Sup
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Natural compounds such as herbal medicines and/or phyto-compounds from foods, have frequently been used to exert synergistic therapeutic effects with anti-brain disorder drugs, supple-ment the effects of nutrients, and boost the immune system. However, co-administration of natural compounds with the drugs can cause synergistic toxicity or impeditive drug interactions due to changes in pharmacokinetic properties (e.g., absorption, metabolism, and excretion) and various drug transporters, particularly brain transporters. In this review, natural compound–drug interactions (NDIs), which can occur during the treatment of brain disorders, are emphasized from the perspective of pharmacokinetics and cellular transport. In addition, the challenges emanating from NDIs and recent approaches are discussed.
AB - Natural compounds such as herbal medicines and/or phyto-compounds from foods, have frequently been used to exert synergistic therapeutic effects with anti-brain disorder drugs, supple-ment the effects of nutrients, and boost the immune system. However, co-administration of natural compounds with the drugs can cause synergistic toxicity or impeditive drug interactions due to changes in pharmacokinetic properties (e.g., absorption, metabolism, and excretion) and various drug transporters, particularly brain transporters. In this review, natural compound–drug interactions (NDIs), which can occur during the treatment of brain disorders, are emphasized from the perspective of pharmacokinetics and cellular transport. In addition, the challenges emanating from NDIs and recent approaches are discussed.
KW - Blood–brain barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB)
KW - Brain disorders
KW - Drug transporters
KW - Natural compound–drug interactions (NDIs)
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=85100654034&partnerID=8YFLogxK
U2 - 10.3390/ijms22041809
DO - 10.3390/ijms22041809
M3 - Review article
C2 - 33670407
AN - SCOPUS:85100654034
SN - 1661-6596
VL - 22
SP - 1
EP - 20
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 4
M1 - 1809
ER -